Neurogene Inc.
NGNE
$29.82
-$1.45-4.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.15M | 20.52M | 17.24M | 19.37M | 17.76M |
| Gross Profit | -25.15M | -20.52M | -17.24M | -19.37M | -17.76M |
| SG&A Expenses | 8.20M | 6.89M | 6.56M | 6.72M | 8.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.35M | 27.41M | 23.80M | 26.08M | 25.92M |
| Operating Income | -33.35M | -27.41M | -23.80M | -26.08M | -25.92M |
| Income Before Tax | -30.93M | -24.74M | -20.95M | -22.02M | -22.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.93M | -24.74M | -20.95M | -22.02M | -22.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.93M | -24.74M | -20.95M | -22.02M | -22.65M |
| EBIT | -33.35M | -27.41M | -23.80M | -26.08M | -25.92M |
| EBITDA | -32.50M | -26.62M | -23.02M | -25.31M | -25.16M |
| EPS Basic | -1.39 | -1.12 | -0.99 | -1.05 | -1.08 |
| Normalized Basic EPS | -0.87 | -0.70 | -0.62 | -0.65 | -0.67 |
| EPS Diluted | -1.39 | -1.12 | -0.99 | -1.05 | -1.08 |
| Normalized Diluted EPS | -0.87 | -0.70 | -0.62 | -0.65 | -0.67 |
| Average Basic Shares Outstanding | 22.31M | 22.08M | 21.17M | 21.06M | 21.00M |
| Average Diluted Shares Outstanding | 22.31M | 22.08M | 21.17M | 21.06M | 21.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |